A simple and selective LC method is described for the determination of Emtricitabine, Rilpivirine and Tenofovirdosage forms. Chromatographic separation was achieved on a c18 column using mobile phase consisting of a mixtureof mixed Phosphate buffer pH: 4: Acetonitrile (40:60v/v/v), with detection of 262nm. Linearity was observed in therange 32.5-97.5 μg /ml for Emtricitabine (r2 =0.9976) 40-120μg/ml for Rilpivirine (r2 =0.996)& 2-6μg /ml forTenofovir (r2 =0.993) for the amount of drugs estimated by the proposed methods was in good agreement with thelabel claim. The proposed methods were validated. The accuracy of the methods was assessed by recovery studies atthree different levels. Recovery experiments indicated the absence of interference from commonly encounteredpharmaceutical additives. The method was found to be precise as indicated by the repeatability analysis, showing%RSD less than 2. All statistical data proves validity of the methods and can be used for routine analysis ofpharmaceutical dosage form.KEY WORDS: Liquid chromatography (LC), RSD Relative standard deviation, r2 correlation coefficient.

A new precise, accurate, rapid method has been developed for the simultaneous estimation of Glycopyrrolate andFormoterol fumaratein pharmaceutical dosage form by RP-UPLC. The optimum wavelength for the determinationof Glycopyrrolate and Formoterol fumaratewas selected at 279 nm on the basis of isobestic point. Various trialswere performed with different mobile phases in different ratios, but finally Water: Acetonitrile: Methanol(20:30:50) %v/v/v was selected as good peak symmetry and resolution between the peaks was observed. TheRetention time of Glycopyrrolate and Formoterol fumarate were found to be 1.208 & 5.934 min respectively. TheRetention times for both the drugs were considerably less compared to the Retention time obtained for the drugs inthe other mobile phase. The different analytical performance parameters such as linearity, precision, accuracy, andspecificity were determined according to International Conference on Harmonization ICH Q2B guidelines. Thecalibration curve was obtained by plotting peak area versus the concentration over the range of 50-120 μg/mLForGlycopyrrolate and 50-120 μg/mL for Formoterol fumarate. From linearity the correlation coefficient R2 value wasfound to be 0.9996for Glycopyrrolateand 0.999 for Formoterol fumarate. The proposed UPLC method was alsovalidated for system suitability, system precision and method precision.KEY WORDS: Glycopyrrolate, Formoterol fumaratein, RP-UPLC

A new precise, accurate, rapid method has been developed for the simultaneous estimation of Glycopyrrolate andFormoterol fumaratein pharmaceutical dosage form by RP-UPLC. The optimum wavelength for the determinationof Glycopyrrolate and Formoterol fumaratewas selected at 279 nm on the basis of isobestic point. Various trialswere performed with different mobile phases in different ratios, but finally Water: Acetonitrile : Methanol(20:30:50) %v/v/v was selected as good peak symmetry and resolution between the peaks was observed.TheRetention time of Glycopyrrolate and Formoterol fumaratewere found to be 1.208 & 5.934 min respectively.The Retention times for both the drugs were considerably less compared to the Retention time obtained for thedrugs in the other mobile phase. The different analytical performance parameters such as linearity, precision,accuracy, and specificity were determined according to International Conference on Harmonization ICH Q2Bguidelines. The calibration curve was obtained by plotting peak area versus the concentration over the range of 50-120 μg/mLFor Glycopyrrolate and50-120 μg/mL forFormoterol fumarate. From linearity the correlationcoefficient R2 value was found to be 0.9996for Glycopyrrolateand 0.999 for Formoterol fumarate. The proposedUPLC method was also validated for system suitability, system precision and method precision.KEY WORDS: Glycopyrrolate, Formoterol fumaratein, RP-UPLC, pharmaceutical dosage form

A simple and selective LC method is described for the determination of Glecaprevir and Pibrentasvir in tabletdosage forms. Chromatographic separation was achieved on a c18 column using mobile phase consisting of amixture of 55 volumes of mixed phosphate buffer and 45 volumes of acetonitrile with detection of 253nm. Linearitywas observed in the range 25-75 μg/ml for Glecaprevir (r2 =0.998) and 50-150 μg /ml for Pibrentasvir (r2 =0.997)for the amount of drugs estimated by the proposed methods was in good agreement with the label claim. Theproposed methods were validated. The accuracy of the methods was assessed by recovery studies at three differentlevels. Recovery experiments indicated the absence of interference from commonly encountered pharmaceuticaladditives. The method was found to be precise as indicated by the repeatability analysis, showing %RSD less than2. All statistical data proves validity of the methods and can be used for routine analysis of pharmaceutical dosageform.KEY WORDS: Glecaprevir, Pibrentasvir, tablet dosage forms

A simple and selective LC method is described for the determination of Metronidazole and Furazolidone in tabletdosage forms. Chromatographic separation was achieved on a C18 column using mobile phase consisting of amixture of 55 volumes of mixed phosphate buffer and 45 volumes of acetonitrile with detection of 266nm. Linearitywas observed in the range 20-60 μg/ml for Metronidazole and 10-30 μg/ml for Furazolidone (r2 =0.999) for theamount of drugs estimated by the proposed methods was in good agreement with the label claim. The proposedmethods were validated. The accuracy of the methods was assessed by recovery studies at three different levels.Recovery experiments indicated the absence of interference from commonly encountered pharmaceutical additives.The method was found to be precise as indicated by the repeatability analysis, showing %RSD less than 2. Allstatistical data proves validity of the methods and can be used for routine analysis of pharmaceutical dosage form..KEY WORDS: Metronidazole, Furazolidone, tablet dosage forms

A new precise, accurate, rapid method has been developed for the estimation of Daclatasvir pharmaceutical dosageform by UPLC. From results the proposed method is highly sensitive, precise and accurate and it successfullyapplied for the quantification of API content in the commercial formulations of Daclatasvir Educational institutionsand Quality control laboratories A simple and selective UPLC method is described for the determination ofDaclatasvir Chromatographic separation was achieved on a Acquity BEH C18 (50*3.0mm. 1.7μm) using mobilephase consisting 0.1% Orthophosphoric acid:Acetonitrile (60:40) v/v with detection of 248 nm. Linearity wasobserved in the range 30-70 μg /ml for Daclatasvir (r2 =0.9987) for the amount of drugs estimated by the proposedmethods was in good agreement with the label claim..KEY WORDS: Daclatasvir, UPLC, pharmaceutical dosage form

A new precise, accurate, rapid method has been developed for the estimation of Exemestane pharmaceutical dosageform by UPLC. From results the proposed method is highly sensitive, precise and accurate and it successfullyapplied for the quantification of API content in the commercial formulations of Exemestane. A simple and selectiveUPLC method is described for the determination of ExemestaneChromatographic separation was achieved onaPhenomenex C18 (250×4.6 ×5μ) using mobile phase consisting Acetonitrile:Water:Triethylaminebuffer (60: 40:0.5%) v/vwith detection of 264 nm. Linearity was observed in the range 50-150 μg /ml for Exemestane(r2 =0.999)for the amount of drugs estimated by the proposed methods was in good agreement with the label claim.KEY WORDS: Exemestane, pharmaceutical dosage form, UPLC

The method described by Touitou et al., (2000) was employed with little modification for the preparation ofvarious ethosomal formulations containing different concentration of ethanol (30 % to 50 %) with sonication . Thetechniques used were simple and reproducible. The prepared ethosomes were spherical and discrete in shape.However ethosomes prepared by sonication method were more uniform and small in size which is essential for skinpenetration. While comparing the entrapment efficiency, ethosomes containing 30% w/w ethanol and prepared bysoncation showed highest value respect to all other formulation; so it is concluded ethosomal prepared bysonication and containing 30 % w/w IPA as the best formulation considering all other aspects Increase in thepolymer concentration led to increase in, % Drug entrapment efficiency, Particle size. The invitro drug releasedecreased with increase in the polymer and copolymer concentration.Among all formulations P6 shows Maximumdrug release in 1440 min when compared with other formulations. Analysis of drug release mechanism showed that thedrug release from the formulations followed the Non fickian diffusion mechanism and follows First orderkinectics.Based on the results of evaluation tests formulation coded P6 was concluded as best formulation.KEY WORDS: Ethosomes , Sonication , Transdermal ,Entrapment , Stability

The main objective of the study was to formulate and evaluate oral thin film containing Prochlorperazine. The 5and 2 % w/v HPMC, PG, CCS films were prepared by solvent casting method. Compatibility of Prochlorperazinewith polymers was confirmed by FT-IR studies. films were evaluated for weight variation and thickness showedsatisfactory results. Tensile strength and folding endurance of the films were increased with increase in theconcentration of polymer due to increase in the elasticity nature of the polymer. Mouth dissolving time anddisintegration time of the films were increased with increase in the concentration of the polymer, as more fluid isrequired to wet the film in the mouth. The presence of disintegrant showed a considerable effect on thedisintegration time of the films. Content uniformity study showed that the drug is uniformly distributed in thefilm. No differences were observed in invitro dissolution of drug from the formulated film p1-p9 as the filminstantly gets wet by dissolution medium. Present study reveals that all the formulated films showed satisfactoryfilm parameters. It can be concluded that, Oral thin film-containing Prochlorperazinecan be prepared by solventcasting method. 5% w/v of HPMC (FV) film exhibited required tensile strength, folding endurance anddisintegration time. The drug release was about 98.6 % in 300 seconds.The accelerated stability studies of theoptimized P8 formulation indicates that the formulated oral thin films were unaffected after 3 months storageunder accelerated conditions as there were no signs of visually distinguishable changes in appearance,disintegration time and cumulative percentage of drug release. From the present investigation it can be concludedthat oral thin film formulation can be a potential novel drug dosage form for pediatric, geriatric and also forgeneral population.KEY WORDS: Prochlorperazine, oral thin film, HPMC, PG, CCS films

The aim of the present study is to formulate Sustained release tablets of Riluzole solid dispersions. Theenhancement of oral bioavailability of poorly water soluble drugs like Riluzole could be improved byenhancing aqueous solubility. Among numerous ways of enhancing drug dissolution, solid dispersions andinclusion complexation are promising techniques to enhance the dissolution of poorly water soluble drugs. Thecalibration curve of Riluzole was obtained in the range of 6 to 14 μg at the wavelength of 278 nm. It hasshown good linearity with a regression coefficient of 0.999 (r2 value). This result exhibit a directrelationship between concentration of polymers and drug release. Among the various formulations tabletsof batch RFD4 demonstrate of drug release (97.8%) with contains 20mg of SSG.KEY WORDS: Riluzole, Sustained release tablets, drug release